Loading...
XNAS
EVO
Market cap1.11bUSD
Dec 05, Last price  
3.12USD
1D
-3.41%
1Q
-10.34%
Jan 2017
-79.96%
Name

Evotec SE

Chart & Performance

D1W1MN
XNAS:EVO chart
P/E
—
P/S
0.60
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.19%
Rev. gr., 5y
12.29%
Revenues
797m
+1.99%
64,115,00067,354,00032,885,00039,613,00042,683,00055,262,00080,128,00087,265,00085,938,00089,496,000127,677,000164,507,000257,630,000375,405,000446,437,000500,924,000618,034,000751,448,000781,426,000796,967,000
Net income
-196m
L+133.67%
-33,583,000-32,468,000-11,156,000-78,287,000-45,497,0003,260,0006,749,0002,478,000-25,433,000-6,978,00016,516,00027,530,00024,257,00084,172,00038,156,0006,278,000215,510,000-175,655,000-83,913,000-196,078,000
CFO
18m
-50.00%
-2,137,000-9,225,000-31,672,000-41,278,000-21,853,000899,00010,146,00011,957,0006,657,000-3,797,00015,651,00067,360,00010,828,000156,240,00042,216,00044,721,000122,237,000203,106,00036,439,00018,220,000
Dividend
Jan 11, 20190.2888 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
URL
https://www.evotec.com/
IPO date
Oct 11, 1999
Employees
5,067
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT